Ophthalmic Solution in Diabetic Corneal Alteration

D&V FARMA srl

Status: Completed

Conditions: Dry Eye Disease (DED)

Treatments: Device: CX-HA and CS

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06573606

DIDI01

Details and patient eligibility

About

Data analyses and revision of the DED symptoms in diabetic subjects. A novel ophthalmic solution containing cross-linked ha (CX-HA) and Chondroitin sulphate (CS) has been made available on the market.

Both molecules have been widely studied for their viscoelastic and hydrating properties.

Nevertheless, the use of CS in ophthalmology has been limited since, routinely, the molecule is of animal origins.

This new ophthalmic solution is the first on the market formulated with a CS of non-animal origin.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diabetic Subjects affected by dry eye disease

Exclusion criteria

• know allergies to CX-HA
• know allergies to CS

Trial design

20 participants in 1 patient group

HA-CS

Description:

Diabetic subjects affected by dry eye disease are treated with the new ophthalmic solution containing cross-linked hyaluronic acid (CX-HA) and Chondroitin sulphate (CS).

Treatment:

Device: CX-HA and CS